Trial
NCT04157517
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Collaborators
—
Condition
Neoplasms
Intervention
Modakafusp Alfa
Why stopped
Study was terminated early due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-29